首页> 美国卫生研究院文献>Pharmaceutics >Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation Characterization and In Vitro Cellular Uptake
【2h】

Doxorubicin–Loaded Human Serum Albumin Submicron Particles: Preparation Characterization and In Vitro Cellular Uptake

机译:阿霉素载人血清白蛋白亚微米颗粒:制备表征和体外细胞吸收。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Doxorubicin (DOX) is an effective anthracycline antibiotic drug which is commonly used in a broad range cancer therapy. However, due to dose depending side effects and toxicity to non-cancerous tissues, its clinical applications are restricted. To overcome these limitations, human serum albumin (HSA) has been investigated as a biocompatible drug delivery vehicle. In this study, human serum albumin submicron particles (HSA-MPs) were fabricated by using the Co-precipitation–Crosslinking–Dissolution technique (CCD technique) and DOX was loaded into the protein particles by absorption. DOX-HSA-MPs showed uniform peanut-like shape, submicron size and negative zeta-potential (−13 mV). The DOX entrapment efficiency was 25% of the initial amount. The in vitro release in phosphate buffered saline pH 7.4 was less than 1% within 5 h. In contrast, up to 40% of the entrapped DOX was released in presence of a protein digesting enzyme mixture (Pronase ) within the same time. In addition, in vitro cytotoxicity and cellular uptake of DOX-HSA-MPs were evaluated using the lung carcinoma cell line A549. The results demonstrated that DOX-HSA-MPs reduced the cell metabolic activities after 72 h. Interestingly, DOX-HSA-MPs were taken up by A549 cells up to 98% and localized in the cell lysosomal compartment. This study suggests that DOX-HSA-MPs which was fabricated by CCD technique is seen as a promising biopolymer particle as well as a viable alternative for drug delivery application to use for cancer therapy.
机译:阿霉素(DOX)是一种有效的蒽环类抗生素药物,通常用于广泛的癌症治疗中。然而,由于剂量依赖性副作用和对非癌组织的毒性,其临床应用受到限制。为了克服这些限制,已经研究了人血清白蛋白(HSA)作为生物相容性药物递送载体。在这项研究中,使用共沉淀-交联-溶解技术(CCD技术)制备了人血清白蛋白亚微米颗粒(HSA-MPs),DOX通过吸收被装载到蛋白质颗粒中。 DOX-HSA-MPs表现出均匀的花生样形状,亚微米尺寸和负ζ电势(-13 mV)。 DOX截留效率为初始量的25%。在磷酸盐缓冲盐水pH 7.4中的体外释放在5小时内小于1%。相反,在同时存在蛋白质消化酶混合物(Pronase)的情况下,最多释放40%的被困DOX。此外,使用肺癌细胞系A549对DOX-HSA-MPs的体外细胞毒性和细胞摄取进行了评估。结果表明,DOX-HSA-MPs在72小时后降低了细胞代谢活性。有趣的是,DOX-HSA-MPs被A549细胞吸收高达98%,并位于细胞溶酶体区室中。这项研究表明,通过CCD技术制造的DOX-HSA-MPs被认为是一种有前途的生物聚合物颗粒,也是用于癌症治疗的药物递送应用的可行替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号